GlassScriptPhysician profile
Renee B Feather
NPI 1528478559
$3,027.98
in general payments reported to CMS, 2019-2025
25 companies · $1,232 in 2025
The $1,232 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2021: $98.99 · 2022: $372 · 2023: $547 · 2024: $641 · 2025: $1,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,420.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $556.63 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $385.12 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $343.50 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $320.06 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Indivior INC. | $219.82 | 2024-2025 | Sublocade |
| Dexcom, INC. | $194.74 | 2022-2024 | Dexcom G6 Transmitter |
| Braeburn INC. | $152.56 | 2024-2025 | Brixadi |
| Glaxosmithkline, LLC. | $104.21 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Merck Sharp & Dohme LLC | $102.51 | 2022-2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $99.97 | 2023-2025 | |
| Viiv Healthcare Company | $83.18 | 2025 | Apretude |
| Exact Sciences Corporation | $68.35 | 2024-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $59.62 | 2022 | |
| Amgen INC. | $51.45 | 2024-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.15 | 2021-2024 | Xifaxan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $43.98 | 2025 | Daybue |
| Xeris Pharmaceuticals, INC. | $41.21 | 2024-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.09 | 2024-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $29.91 | 2022-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.21 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $16.81 | 2022 | |
| Sumitomo Pharma America, INC. | $16.46 | 2024 | Gemtesa |
| Melinta Therapeutics, LLC | $13.92 | 2019 | |
| Almatica Pharma LLC | $13.85 | 2021 | |
| Abbott Laboratories | $13.67 | 2024 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Renee Feather listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.